ACSL4 shRNA Plasmid (h) from Santa Cruz Biotechnology, Inc. | Biocompare.com

Supplier Images

ACSL4 shRNA Plasmid (h)

Be the first to write a review!

Citations:

Supplier Page from
Santa Cruz Biotechnology, Inc. for
ACSL4 shRNA Plasmid (h)

Product Specs
ItemACSL4 shRNA Plasmid (h)
CompanySanta Cruz Biotechnology, Inc.
Price $592.00Supplier Page View Company Product Page
Catalog Numbersc-60619-SH
Quantity20 µg
RNA TypeshRNA Clones
Vector Type (Standardized)Lentiviral
TypeshRNA Plasmid
Specieshuman
NCBI Full Gene Nameacyl-CoA synthetase long chain family member 4
NCBI Gene AliasesACS4, FACL4, LACS4, MRX63, MRX68, XLID63

Add to Compare List

Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Alpha synuclein determines ferroptosis sensitivity in dopaminergic neurons via modulation of ether-phospholipid membrane compositionCell reportsAugust 23, 2022Mahoney-Sanchez L, Bouchaoui H, Boussaad I, Jonneaux A, Timmerman K, Berdeaux O, Ayton S, Krüger R, Duce JA, Devos D, et al.

(2) ACSL4 promotes colorectal cancer and is a potential therapeutic target of emodinPhytomedicine : international journal of phytotherapy and phytopharmacologyJuly 20, 2022Dai G, Wang D, Ma S, Hong S, Ding K, Tan X, Ju W.

(3) Fatty acid oxidation protects cancer cells from apoptosis by increasing mitochondrial membrane lipidsCell reportsJune 28, 2022Li YJ, Fahrmann JF, Aftabizadeh M, Zhao Q, Tripathi SC, Zhang C, Yuan Y, Ann D, Hanash S, Yu H.

(4) Fatty acid oxidation protects cancer cells from apoptosis by increasing mitochondrial membrane lipidsCell reportsMay 31, 2022Li YJ, Fahrmann JF, Aftabizadeh M, Zhao Q, Tripathi SC, Zhang C, Yuan Y, Ann D, Hanash S, Yu H.

(5) Acyl-CoA synthetase-4 mediates radioresistance of breast cancer cells by regulating FOXM1Biochemical pharmacologyOctober 1, 2021Kwon YS, Lee MG, Baek J, Kim NY, Jang H, Kim S.

(6) ACSL4 suppresses glioma cells proliferation via activating ferroptosisOncology reportsJanuary 1, 2020Cheng J, Fan YQ, Liu BH, Zhou H, Wang JM, Chen QX.

Be the First to Write a Review!